Terms: = Colorectal cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA
643 results:
1. atm inhibition enhance immunotherapy by activating STING signaling and augmenting MHC Class I.
Li C; Wang B; Tu J; Liu C; Wang Y; Chen J; Huang Y; Liu B; Yuan X
Cell Death Dis; 2024 Jul; 15(7):519. PubMed ID: 39033176
[TBL] [Abstract] [Full Text] [Related]
2. TOPK Inhibition Enhances the Sensitivity of colorectal cancer Cells to Radiotherapy by Reducing the DNA Damage Response.
Pang SG; Zhang X; Li ZX; He LF; Chen F; Liu ML; Huang YZ; Mo JM; Luo KL; Xiao JJ; Zhu F
Curr Med Sci; 2024 Jun; 44(3):545-553. PubMed ID: 38900386
[TBL] [Abstract] [Full Text] [Related]
3. The novel SMYD3 inhibitor EM127 impairs DNA repair response to chemotherapy-induced DNA damage and reverses cancer chemoresistance.
Sanese P; De Marco K; Lepore Signorile M; La Rocca F; Forte G; Latrofa M; Fasano C; Disciglio V; Di Nicola E; Pantaleo A; Bianco G; Spilotro V; Ferroni C; Tubertini M; Labarile N; De Marinis L; Armentano R; Gigante G; Lantone V; Lantone G; Naldi M; Bartolini M; Varchi G; Del Rio A; Grossi V; Simone C
J Exp Clin Cancer Res; 2024 May; 43(1):151. PubMed ID: 38812026
[TBL] [Abstract] [Full Text] [Related]
4. Distinct Driver Pathway Enrichments and a High Prevalence of
Tapia-Valladares C; Valenzuela G; González E; Maureira I; Toro J; Freire M; Sepúlveda-Hermosilla G; Ampuero D; Blanco A; Gallegos I; Morales F; Erices JI; Barajas O; Ahumada M; Contreras HR; González J; Armisén R; Marcelain K
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731914
[TBL] [Abstract] [Full Text] [Related]
5. Discovery of a Meisoindigo-Derived PROTAC as the atm Degrader: Revolutionizing colorectal cancer Therapy via Synthetic Lethality with ATR Inhibitors.
Liu TT; Wang Q; Zhou Y; Ye B; Liu T; Yan L; Fan J; Xu J; Zhou Y; Xia Z; Deng X
J Med Chem; 2024 May; 67(9):7620-7634. PubMed ID: 38634707
[TBL] [Abstract] [Full Text] [Related]
6. Synergistic targeting of TrxR1 and atm/AKT pathway in human colon cancer cells.
Shen X; Xia Y; Lu H; Zheng P; Wang J; Chen Y; Xu C; Qiu C; Zhang Y; Xiao Z; Zou P; Cui R; Ni D
Biomed Pharmacother; 2024 May; 174():116507. PubMed ID: 38565059
[TBL] [Abstract] [Full Text] [Related]
7. The feasibility and acceptability of an app-based intervention with brief behavioural support (APPROACH) to promote brisk walking in people diagnosed with breast, prostate and colorectal cancer in the UK.
Lally P; Kennedy F; Smith S; Beeken RJ; Buck C; Thomas C; Counsell N; Wyld L; Martin C; Williams S; Roberts A; Greenfield DM; Gath J; Potts HWW; Latimer N; Smith L; Fisher A
Cancer Med; 2024 Mar; 13(6):e7124. PubMed ID: 38529687
[TBL] [Abstract] [Full Text] [Related]
8. Canonical DDR activation by EMT inducing agent 5-Fluorouracil is modulated by a cannabinoid based combinatorial approach via inducing autophagy and suppression of vimentin expression.
Mir KB; Chakraborty S; Amin T; Kumar A; Rouf War A; Nalli Y; Kumar R; Dinesh Kumar L; Ali A; Goswami A
Biochem Pharmacol; 2024 May; 223():116126. PubMed ID: 38490521
[TBL] [Abstract] [Full Text] [Related]
9. Type 2 diabetes mellitus and post-colonoscopy colorectal cancer: clinical and molecular characteristics and survival.
Boysen ML; Troelsen FS; Sørensen HT; Erichsen R
Cancer Causes Control; 2024 Jul; 35(7):1043-1052. PubMed ID: 38483686
[TBL] [Abstract] [Full Text] [Related]
10. Examining cancer screening disparities by race/ethnicity and insurance groups: A comparison of 2008 and 2018 National Health Interview Survey (NHIS) data in the United States.
Sun J; Frick KD; Liang H; Chow CM; Aronowitz S; Shi L
PLoS One; 2024; 19(2):e0290105. PubMed ID: 38416784
[TBL] [Abstract] [Full Text] [Related]
11. Genome-wide association studies and Mendelian randomization analyses provide insights into the causes of early-onset colorectal cancer.
Laskar RS; Qu C; Huyghe JR; Harrison T; Hayes RB; Cao Y; Campbell PT; Steinfelder R; Talukdar FR; Brenner H; Ogino S; Brendt S; Bishop DT; Buchanan DD; Chan AT; Cotterchio M; Gruber SB; Gsur A; van Guelpen B; Jenkins MA; Keku TO; Lynch BM; Le Marchand L; Martin RM; McCarthy K; Moreno V; Pearlman R; Song M; Tsilidis KK; Vodička P; Woods MO; Wu K; Hsu L; Gunter MJ; Peters U; Murphy N;
Ann Oncol; 2024 Jun; 35(6):523-536. PubMed ID: 38408508
[TBL] [Abstract] [Full Text] [Related]
12. Integrated bioinformatics approach to unwind key genes and pathways involved in colorectal cancer.
Mobeen SA; Saxena P; Jain AK; Deval R; Riazunnisa K; Pradhan D
J Cancer Res Ther; 2023 Oct; 19(7):1766-1774. PubMed ID: 38376276
[TBL] [Abstract] [Full Text] [Related]
13. Dietary phytoestrogen intake and ovarian cancer risk: a prospective study in the prostate, lung, colorectal and ovarian (PLCO) cohort.
Song Y; Huang H; Jin M; Cheng B; Wang S; Yang X; Hu X
Carcinogenesis; 2024 Jun; 45(6):378-386. PubMed ID: 38375679
[TBL] [Abstract] [Full Text] [Related]
14. Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to atm and ATR inhibitors.
Aubert L; Bastien E; Renoult O; Guilbaud C; Özkan K; Brusa D; Bouzin C; Richiardone E; Richard C; Boidot R; Léonard D; Corbet C; Feron O
EMBO Rep; 2024 Mar; 25(3):1469-1489. PubMed ID: 38366255
[TBL] [Abstract] [Full Text] [Related]
15. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in colorectal cancer.
Singh H; Sahgal P; Kapner K; Corsello SM; Gupta H; Gujrathi R; Li YY; Cherniack AD; El Alam R; Kerfoot J; Andrews E; Lee A; Nambiar C; Hannigan AM; Remland J; Brais L; Leahy ME; Rubinson DA; Schlechter BL; Meyerson M; Kuang Y; Paweletz CP; Lee JK; Quintanilha JCF; Aguirre AJ; Perez KJ; Huffman BM; Rossi H; Abrams TA; Kabraji S; Trusolino L; Bertotti A; Sicinska ET; Parikh AR; Wolpin BM; Schrock AB; Giannakis M; Ng K; Meyerhardt JA; Hornick JL; Sethi NS; Cleary JM
Clin Cancer Res; 2024 Apr; 30(8):1669-1684. PubMed ID: 38345769
[TBL] [Abstract] [Full Text] [Related]
16. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal cancers.
Ngoi NYL; Tang TY; Gaspar CF; Pavlick DC; Buchold GM; Scholefield EL; Parimi V; Huang RSP; Janovitz T; Danziger N; Levy MA; Pant S; De Armas AD; Kumpula D; Ross JS; Javle M; Rodon Ahnert J
Oncologist; 2024 Jun; 29(6):493-503. PubMed ID: 38330461
[TBL] [Abstract] [Full Text] [Related]
17. Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment.
Huang L; Shao J; Lai W; Gu H; Yang J; Shi S; Wufoyrwoth S; Song Z; Zou Y; Xu Y; Zhu Q
Eur J Med Chem; 2024 Mar; 267():116159. PubMed ID: 38325007
[TBL] [Abstract] [Full Text] [Related]
18. Alterations in the gut microbiota and their metabolites in human intestinal epithelial cells of patients with colorectal cancer.
Jahani-Sherafat S; Azimirad M; Raeisi H; Azizmohammad Looha M; Tavakkoli S; Ahmadi Amoli H; Moghim S; Rostami-Nejad M; Yadegar A; Zali MR
Mol Biol Rep; 2024 Feb; 51(1):265. PubMed ID: 38302841
[TBL] [Abstract] [Full Text] [Related]
19. Methylation of NRIP3 Is a Synthetic Lethal Marker for Combined PI3K and ATR/atm Inhibitors in colorectal cancer.
Zhang M; Li X; Herman JG; Gao A; Wang Q; Yao Y; Shen F; He K; Guo M
Clin Transl Gastroenterol; 2024 Mar; 15(3):e00682. PubMed ID: 38235705
[TBL] [Abstract] [Full Text] [Related]
20. Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells.
Sogari A; Rovera E; Grasso G; Mariella E; Reilly NM; Lamba S; Mauri G; Durinikova E; Vitiello PP; Lorenzato A; Avolio M; Piumatti E; Bonoldi E; Aquilano MC; Arena S; Sartore-Bianchi A; Siena S; Trusolino L; Donalisio M; Russo M; Di Nicolantonio F; Lembo D; Bardelli A
Cell Rep Med; 2024 Feb; 5(2):101376. PubMed ID: 38228147
[TBL] [Abstract] [Full Text] [Related]
[Next]
